SCH 900962, ORG 36286--FSH-R AGONIST THE FIRST SUSTAINED FOLLICLE STIMULANT INN CORIFOLLITROPIN ALFA
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $14,155 | 1 | 0 |
| 2017 | $8,500 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $22,655 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase III, randomized, double blind, active-controlled, non-inferiority trial to investigate the efficacy and safety of a single injection of SCH 900962 corifollitropin alfa to induce multifollicular development for controlled ovarian stimulation COS using daily recombinant FSH as a reference | Merck Sharp & Dohme Corporation | $14,155 | 0 |
| A phase III, multi-center, open label, single-group trial to investigate the efficacy and safety of MK-8962 corifollitropin alfa in combination with human Chorionic Gonadotropin hCG for initiation or restoration of puberty as assessed by increased testicular volume in adolescent males 14 to 18 years old with hypogonadotropic hypogonadism | Merck Sharp & Dohme Corporation | $8,500 | 0 |
Top Doctors Receiving Payments for SCH 900962, ORG 36286--FSH-R AGONIST THE FIRST SUSTAINED FOLLICLE STIMULANT INN CORIFOLLITROPIN ALFA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $22,655 | 2 |
Manufacturing Companies
- Merck Sharp & Dohme Corporation $22,655
Product Information
- Type Drug
- Total Payments $22,655
- Total Doctors 0
- Transactions 2
About SCH 900962, ORG 36286--FSH-R AGONIST THE FIRST SUSTAINED FOLLICLE STIMULANT INN CORIFOLLITROPIN ALFA
SCH 900962, ORG 36286--FSH-R AGONIST THE FIRST SUSTAINED FOLLICLE STIMULANT INN CORIFOLLITROPIN ALFA is a drug associated with $22,655 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2019. In 2019, $14,155 was paid across 1 transactions to 0 doctors.
The most common payment nature for SCH 900962, ORG 36286--FSH-R AGONIST THE FIRST SUSTAINED FOLLICLE STIMULANT INN CORIFOLLITROPIN ALFA is "Unspecified" ($22,655, 100.0% of total).
SCH 900962, ORG 36286--FSH-R AGONIST THE FIRST SUSTAINED FOLLICLE STIMULANT INN CORIFOLLITROPIN ALFA is associated with 2 research studies, including "Phase III, randomized, double blind, active-controlled, non-inferiority trial to investigate the efficacy and safety of a single injection of SCH 900962 corifollitropin alfa to induce multifollicular development for controlled ovarian stimulation COS using daily recombinant FSH as a reference" ($14,155).